OpenLB
Open Library of Bioscience
Advanced Search
Biologics : targets & therapy
2021;15 205-219.

Monoclonal Antibody Therapies for High Risk Neuroblastoma.

Wayne L Furman
Author Information
  1. Wayne L Furman: Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. ORCID
PMID: 34135571 DOI: 10.2147/BTT.S267278

Abstract

Monoclonal antibodies (mAbs) are part of the standard of care for the treatment of many adult solid tumors. Until recently none have been approved for use in children with solid tumors. Neuroblastoma (NB) is the most common extracranial solid tumor in children. Those with high-risk disease, despite treatment with very intensive multimodal therapy, still have poor overall survival. Results of treatment with an immunotherapy regimen using a chimeric (human/mouse) mAb against a cell surface disialoganglioside (GD2) have changed the standard of care for these children and resulted in the first approval of a mAb for use in children with solid tumors. This article will review the use of the various anti-GD2 mAbs in children with NB, methods that have been or are being evaluated for enhancing their efficacy, as well as review other promising antigenic targets for the therapeutic use of mAbs in children with NB.

Keywords

anti-GD2 anti-disialoganglioside chimeric effector cells immunotherapy neuroblastoma

References

  1. Int J Oncol. 1993 Nov;3(5):909-15 [PMID: 21573452]
  2. J Neurol Sci. 1997 Aug;149(2):127-30 [PMID: 9171318]
  3. Cancer Res. 1987 Feb 15;47(4):1098-104 [PMID: 3100030]
  4. PLoS One. 2011;6(9):e25220 [PMID: 21966461]
  5. Clin Cancer Res. 2007 Jul 1;13(13):3942-50 [PMID: 17606728]
  6. Nat Rev Immunol. 2008 Jan;8(1):59-73 [PMID: 18097448]
  7. Lancet Oncol. 2018 Dec;19(12):1617-1629 [PMID: 30442501]
  8. MAbs. 2010 May-Jun;2(3):256-65 [PMID: 20400861]
  9. J Immunol Res. 2017;2017:5604891 [PMID: 28154831]
  10. Oncoimmunology. 2015 May 22;4(7):e1016704 [PMID: 26140243]
  11. Immunology. 2011 Feb;132(2):226-39 [PMID: 21039467]
  12. Front Immunol. 2018 Feb 15;9:283 [PMID: 29497427]
  13. Expert Opin Investig Drugs. 2009 Jul;18(7):991-1000 [PMID: 19548853]
  14. J Nucl Med. 1991 May;32(5):769-76 [PMID: 1902508]
  15. Clin Cancer Res. 2002 May;8(5):1217-23 [PMID: 12006541]
  16. JAMA Oncol. 2018 Dec 1;4(12):1729-1735 [PMID: 30326045]
  17. Curr Opin Pediatr. 2005 Feb;17(1):7-13 [PMID: 15659956]
  18. Oncoimmunology. 2017 Jul 31;6(11):e1358331 [PMID: 29147617]
  19. BMC Cancer. 2014 Apr 28;14:295 [PMID: 24773917]
  20. J Pediatr Hematol Oncol. 2001 Oct;23(7):437-42 [PMID: 11878578]
  21. Cancer Immunol Immunother. 1992;35(3):199-204 [PMID: 1638557]
  22. J Biomed Sci. 2020 Jan 2;27(1):1 [PMID: 31894001]
  23. Semin Cancer Biol. 2012 Feb;22(1):3-13 [PMID: 22245472]
  24. J Clin Oncol. 2004 Sep 1;22(17):3549-57 [PMID: 15337804]
  25. Cancers (Basel). 2019 Oct 11;11(10): [PMID: 31614472]
  26. J Nucl Med. 2012 Nov;53(11):1772-8 [PMID: 23064212]
  27. Oncoimmunology. 2017 Jul 5;6(10):e1343775 [PMID: 29123953]
  28. MAbs. 2016;8(3):604-16 [PMID: 26785755]
  29. MAbs. 2018 Jan;10(1):55-61 [PMID: 29120699]
  30. Trends Cancer. 2018 Nov;4(11):741-754 [PMID: 30352677]
  31. Cancer Lett. 2009 Aug 28;281(2):171-82 [PMID: 19339105]
  32. J Clin Oncol. 2007 Dec 1;25(34):5465-70 [PMID: 18048828]
  33. Cell Res. 2017 Jan;27(1):109-118 [PMID: 27995907]
  34. Int J Mol Med. 2001 Nov;8(5):579-84 [PMID: 11605031]
  35. Oncoimmunology. 2018 May 10;7(8):e1461305 [PMID: 30221057]
  36. Curr Opin Pediatr. 2018 Feb;30(1):30-39 [PMID: 29189429]
  37. Cancer Res. 1990 Sep 1;50(17):5234-9 [PMID: 2386933]
  38. Immunotherapy. 2016 Sep;8(9):1097-117 [PMID: 27485082]
  39. Cancer Res. 2003 Aug 1;63(15):4490-6 [PMID: 12907622]
  40. Lab Invest. 1996 Nov;75(5):659-75 [PMID: 8941212]
  41. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S121-7 [PMID: 9457407]
  42. J Clin Oncol. 2012 Sep 10;30(26):3264-70 [PMID: 22869886]
  43. Cancer Lett. 2003 Jul 18;197(1-2):205-9 [PMID: 12880983]
  44. Lancet Oncol. 2017 Jul;18(7):946-957 [PMID: 28549783]
  45. Semin Oncol. 2020 Apr - Jun;47(2-3):117-124 [PMID: 32517874]
  46. Cancer Res. 1985 Jun;45(6):2642-9 [PMID: 2580625]
  47. Cancer Cell. 2017 Sep 11;32(3):295-309.e12 [PMID: 28898695]
  48. J Clin Oncol. 2020 Jun 1;38(16):1836-1848 [PMID: 32167865]
  49. Curr Cancer Drug Targets. 2010 Mar;10(2):200-9 [PMID: 20201786]
  50. Oncoimmunology. 2012 Jul 1;1(4):477-486 [PMID: 22754766]
  51. J Immunother Emphasis Tumor Immunol. 1996 Jul;19(4):278-95 [PMID: 8877722]
  52. J Immunol. 2012 Sep 1;189(5):2656-64 [PMID: 22844125]
  53. Cancer Res. 2001 May 15;61(10):4048-54 [PMID: 11358824]
  54. J Clin Oncol. 2014 May 10;32(14):1445-52 [PMID: 24711551]
  55. Clin Cancer Res. 2019 Jan 1;25(1):325-333 [PMID: 30232225]
  56. Cancer Res. 1994 Apr 15;54(8):2228-33 [PMID: 8174131]
  57. J Immunother Emphasis Tumor Immunol. 1996 May;19(3):206-17 [PMID: 8811495]
  58. Oncoimmunology. 2015 Jul 15;5(1):e1064578 [PMID: 26942080]
  59. J Clin Oncol. 2000 Dec 15;18(24):4077-85 [PMID: 11118469]
  60. Med Pediatr Oncol. 2001 Jan;36(1):227-30 [PMID: 11464891]
  61. J Clin Oncol. 1998 Sep;16(9):3053-60 [PMID: 9738575]
  62. J Cell Biol. 1986 Mar;102(3):688-96 [PMID: 3005335]
  63. Nat Rev Cancer. 2005 May;5(5):397-405 [PMID: 15864281]
  64. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5613s-5620s [PMID: 17875797]
  65. Immunopharmacology. 1997 Oct;37(2-3):117-32 [PMID: 9403331]
  66. Histopathology. 2008 Jul;53(1):73-80 [PMID: 18613926]
  67. J Biol Chem. 2015 Dec 11;290(50):30018-29 [PMID: 26487718]
  68. Front Oncol. 2020 Jul 07;10:1000 [PMID: 32733795]
  69. J Clin Oncol. 1998 Jun;16(6):2169-80 [PMID: 9626218]
  70. Mol Immunol. 2000 Nov;37(16):995-1004 [PMID: 11395138]
  71. Clin Cancer Res. 2001 Sep;7(9):2862-9 [PMID: 11555604]
  72. J Clin Oncol. 2001 Nov 15;19(22):4189-94 [PMID: 11709561]
  73. Expert Opin Drug Metab Toxicol. 2012 Feb;8(2):141-60 [PMID: 22248267]
  74. Cancer Immunol Immunother. 2008 Nov;57(11):1579-87 [PMID: 18369619]
  75. Cancers (Basel). 2020 Jan 28;12(2): [PMID: 32013055]
  76. Ther Adv Med Oncol. 2020 Oct 4;12:1758835920962997 [PMID: 33088347]
  77. J Immunother Cancer. 2020 May;8(1): [PMID: 32414861]
  78. Blood. 2011 Dec 1;118(23):6050-6 [PMID: 21984804]
  79. J Clin Oncol. 2010 Nov 20;28(33):4969-75 [PMID: 20921469]
  80. J Clin Oncol. 2020 Jul 1;38(19):2160-2169 [PMID: 32343642]
  81. Cytotechnology. 2007 Dec;55(2-3):109-14 [PMID: 19003000]
  82. Cancer Immunol Immunother. 1995 Jul;41(1):29-36 [PMID: 7641217]
  83. J Neurooncol. 2010 May;97(3):409-18 [PMID: 19890606]
  84. Pediatr Blood Cancer. 2015 Feb;62(2):224-228 [PMID: 25382742]
  85. Expert Opin Ther Targets. 2015 Mar;19(3):349-62 [PMID: 25604432]
  86. Cancer Cell. 2014 Nov 10;26(5):682-94 [PMID: 25517749]
  87. PLoS One. 2014 Feb 10;9(2):e87210 [PMID: 24520328]
  88. J Clin Oncol. 2012 Oct 1;30(28):3525-32 [PMID: 22927533]
  89. J Nucl Med. 2005 Jan;46 Suppl 1:157S-63S [PMID: 15653664]
  90. Nat Rev Immunol. 2010 May;10(5):317-27 [PMID: 20414205]
  91. Cancer Chemother Pharmacol. 2014 Nov;74(5):1047-55 [PMID: 25212536]
  92. Nat Rev Dis Primers. 2016 Nov 10;2:16078 [PMID: 27830764]
  93. Cell Mol Life Sci. 2010 Jun;67(11):1845-58 [PMID: 20165901]
  94. Discov Med. 2013 Dec;16(90):287-94 [PMID: 24333408]
  95. Cancer Immunol Immunother. 2018 Apr;67(4):615-626 [PMID: 29327110]
  96. Eur J Cancer. 1995;31A(2):256-61 [PMID: 7718334]
  97. Clin Cancer Res. 2019 Dec 15;25(24):7554-7564 [PMID: 31455682]
  98. Front Immunol. 2018 Oct 16;9:2380 [PMID: 30459759]
  99. Cancer Cell. 2019 Feb 11;35(2):221-237.e8 [PMID: 30753824]
  100. Cancer Biol Ther. 2014 Jul;15(7):851-61 [PMID: 24755919]
  101. Clin Cancer Res. 2016 Jul 15;22(14):3425-3431 [PMID: 27208063]
  102. Lancet. 2007 Jun 23;369(9579):2106-20 [PMID: 17586306]
  103. J Clin Oncol. 1994 Jan;12(1):184-93 [PMID: 8270976]
  104. Blood. 2007 May 15;109(10):4245-8 [PMID: 17264296]
  105. Lancet Oncol. 2018 Dec;19(12):1549-1551 [PMID: 30442498]
  106. Nat Rev Cancer. 2012 Mar 22;12(4):252-64 [PMID: 22437870]
  107. Cancer Res. 1989 Jun 1;49(11):2857-61 [PMID: 2720646]
  108. N Engl J Med. 2010 Sep 30;363(14):1324-34 [PMID: 20879881]
  109. Cancer Res. 1991 Jan 1;51(1):144-9 [PMID: 1988079]
  110. Clin Cancer Res. 2006 Mar 15;12(6):1750-9 [PMID: 16551859]
  111. Pediatr Blood Cancer. 2012 Dec 15;59(7):1198-205 [PMID: 22707078]
  112. Sci Transl Med. 2019 Mar 13;11(483): [PMID: 30867324]
  113. Eur J Immunol. 2004 Feb;34(2):336-44 [PMID: 14768038]
  114. Int J Oncol. 1998 Jun;12(6):1299-306 [PMID: 9592190]
  115. J Immunol. 1990 Feb 15;144(4):1382-6 [PMID: 2303711]
  116. Front Immunol. 2020 Jan 28;11:18 [PMID: 32082311]
  117. Blood. 1989 May 15;73(7):1936-41 [PMID: 2653466]
  118. Med Pediatr Oncol. 2000 Dec;35(6):716-8 [PMID: 11107154]
  119. Clin Cancer Res. 2019 Nov 1;25(21):6320-6328 [PMID: 31601569]
  120. Eur J Cancer. 1995;31A(2):261-7 [PMID: 7718335]
  121. J Biol Chem. 2002 Jul 26;277(30):26733-40 [PMID: 11986321]
  122. Jpn J Cancer Res. 2002 Jul;93(7):816-24 [PMID: 12149148]
  123. J Clin Oncol. 2012 Feb 1;30(4):426-32 [PMID: 22203761]
  124. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588 [PMID: 28653357]
  125. J Clin Oncol. 2009 Jan 1;27(1):85-91 [PMID: 19047298]
  126. J Immunol. 2003 May 15;170(10):4905-13 [PMID: 12734333]
  127. Int J Cancer. 2014 Nov 1;135(9):2199-205 [PMID: 24644014]
  128. Cell. 2009 Jul 23;138(2):271-85 [PMID: 19632178]
  129. Pain. 2010 Apr;149(1):135-142 [PMID: 20171010]
  130. MAbs. 2013 Sep-Oct;5(5):801-9 [PMID: 23924804]
  131. Biomolecules. 2019 Jul 27;9(8): [PMID: 31357634]
  132. J Clin Oncol. 1987 Sep;5(9):1430-40 [PMID: 3625258]
  133. Oncogene. 2012 Nov 15;31(46):4859-67 [PMID: 22266870]
  134. Cancer. 1993 Jul 15;72(2):623-8 [PMID: 8319196]
  135. Clin Cancer Res. 1997 Aug;3(8):1277-88 [PMID: 9815810]
  136. Hum Antibodies Hybridomas. 1992 Jan;3(1):19-24 [PMID: 1576319]
  137. Cancer Res. 1986 Jan;46(1):440-3 [PMID: 3940209]
  138. Clin Pharmacol Ther. 2008 Nov;84(5):548-58 [PMID: 18784655]
  139. Mol Immunol. 2005 Jul;42(11):1311-9 [PMID: 15950727]
  140. Nat Rev Drug Discov. 2019 Aug;18(8):585-608 [PMID: 31175342]
  141. Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12640-5 [PMID: 15314238]
  142. Expert Rev Mol Med. 2007 Dec 17;9(34):1-21 [PMID: 18081947]
  143. Cancer. 1997 Jul 15;80(2):317-33 [PMID: 9217046]
  144. J Pharm Sci. 2004 Nov;93(11):2645-68 [PMID: 15389672]
  145. Front Immunol. 2019 Dec 03;10:2816 [PMID: 31849984]
  146. Clin Pharmacokinet. 2013 Feb;52(2):83-124 [PMID: 23299465]
  147. N Engl J Med. 2010 Jun 10;362(23):2202-11 [PMID: 20558371]
Journal Article Review
Article has an altmetric score of 2

Word Cloud

Created with Highcharts 10.0.0childrensolidusemAbstreatmenttumorsNBMonoclonalstandardcareNeuroblastomaimmunotherapychimericmAbreviewanti-GD2antibodiespartmanyadultrecentlynoneapprovedcommonextracranialtumorhigh-riskdiseasedespiteintensivemultimodaltherapystillpooroverallsurvivalResultsregimenusinghuman/mousecellsurfacedisialogangliosideGD2changedresultedfirstapprovalarticlewillvariousmethodsevaluatedenhancingefficacywellpromisingantigenictargetstherapeuticAntibodyTherapiesHighRiskanti-disialogangliosideeffectorcellsneuroblastoma

Similar Articles

Cited By